Company / R&D Expense
Larimar Therapeutics, Inc. R&D Expense History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$40.8M
FY2019
5-year range
$9.6M / $54.6M
FY2015-FY2019
Trend
+2.3%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has fluctuated over the past 6 years, ranging from $10M in FY2015 to $55M in FY2017.
Based on SEC 10-K filings.
$41M in FY2019 with a 5-year CAGR of +28.7%.
Declined from $55M to $41M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +14.2%
- 5-Year CAGR
- +28.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +28.7%, indicating consistent growth.
- In FY2019, r&d expense increased 2.3% year-over-year.
- Peak r&d expense was recorded in FY2017.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $40.8M | +2.3% |
| FY2018 | $39.9M | -26.9% |
| FY2017 | $54.6M | +99.4% |
| FY2016 | $27.4M | +186.5% |
| FY2015 | $9.6M | -17.2% |
| FY2014 | $11.5M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026